Biosimilars: Exploring the History, Science, and Progress

Clinical Journal of Oncology Nursing
Joseph D Tariman

Abstract

Biosimilars provide opportunities for improving healthcare access and outcomes and reducing overall healthcare costs for patients with cancer. The purpose of this article is to explore the history of biosimilars, regulatory pathways, and barriers to biosimilar approval. This article also aims to describe the patient and clinician barriers to biosimilars use and the progress that has been achieved since the first biosimilar approval in Europe in 2006 and in the United States in 2015. A literature search was conducted to retrieve articles that are highly relevant to the history of biosimilars development and regulatory pathways in the United States, Europe, Asia, and Canada. Patient and clinician perspectives on safety issues and concerns regarding immunogenicity and bioequivalence that limit use of biosimilars are also included. Patient and provider concerns regarding immunologic patient safety issues, such as immunogenicity, lack of comparability, and low biosimilarity, still exist. The clinical safety, efficacy, and tolerability of biosimilars are among the top concerns in patients, prescribers, and clinicians.

References

Mar 1, 1997·Current Opinion in Oncology·M B Atkins
Feb 12, 2002·Seminars in Oncology·Anna K NowakBruce W S Robinson
Nov 5, 2002·Current Opinion in Immunology·Gerald T Nepom
Feb 14, 2003·The New England Journal of Medicine·Filip BaertPaul Rutgeerts
Sep 2, 2003·Nature Biotechnology·Sabine Louët
Oct 7, 2004·Journal of the American Society of Nephrology : JASN·Denis CournoyerUNKNOWN Canadian PRCA Focus Group
Nov 6, 2004·Nature Biotechnology·Karl A Thiel
Dec 21, 2004·European Journal of Clinical Investigation·H Schellekens
May 12, 1972·Science·B J Culliton
Sep 25, 2007·Clinical and Experimental Nephrology·David GoldsmithAdrian Covic
Aug 30, 1884·British Medical Journal·R Koch
Jan 17, 1891·British Medical Journal·R Koch
Nov 19, 2010·Rheumatology·Julia F SimardJohan Askling
Apr 14, 2011·JAMA : the Journal of the American Medical Association·Geertje M BarteldsGerrit Jan Wolbink
Jul 26, 2011·Biologicals : Journal of the International Association of Biological Standardization·Martin Schiestl
Dec 20, 2011·Clinical Pharmacology and Therapeutics·G R Woollett
Feb 10, 2012·Clinical Pharmacology and Therapeutics·Mark McCamish, Gillian Woollett
May 12, 2012·Cancer Discovery·Katherine Bourzac
Feb 13, 2013·Nature Reviews. Rheumatology·Pauline A van SchouwenburgGerrit Jan Wolbink
Jan 1, 2014·Biologicals : Journal of the International Association of Biological Standardization·Martin SchiestlHye-Na Kang
Dec 3, 2014·The Lancet Oncology·Charles L BennettJames O Armitage
Feb 6, 2015·Nature Medicine·Cassandra Willyard
Feb 12, 2015·Clinical Pharmacology and Therapeutics·M McCamishG Woollett
Mar 21, 2015·Cancer Discovery·Janet Colwell
May 1, 2015·Nature Reviews. Drug Discovery·Courtenay C Brinckerhoff, Kristel Schorr
Jul 5, 2015·Journal of the National Cancer Institute·Karyn Hede
Nov 5, 2015·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·K TanabeY Fujimoto
Feb 3, 2016·Bulletin du cancer·Dominique Levêque
Mar 8, 2016·Seminars in Arthritis and Rheumatism·Ahmad Al-SabbaghCarol F Kirchhoff
Mar 8, 2016·Nature Reviews. Nephrology·Stephen R HoldsworthA Richard Kitching
Jun 17, 2016·Patient Preference and Adherence·Ira JacobsLesley G Shane
Nov 1, 2016·Advances in Therapy·Hillel CohenJonathan Uy
Jan 7, 2017·Journal of Pharmacy & Pharmaceutical Sciences : a Publication of the Canadian Society for Pharmaceutical Sciences, Société Canadienne Des Sciences Pharmaceutiques·Prasanta Kumar Ghosh
Jan 12, 2017·Clinical Pharmacology and Therapeutics·M McCamish, G R Woollett
Feb 13, 2017·The Nursing Clinics of North America·Joseph D Tariman
Apr 19, 2017·Clinical Therapeutics·Corrado BlandizziGiovanni Lapadula
May 4, 2017·Therapeutic Drug Monitoring·Karien BloemTheo Rispens
May 30, 2017·Drug Design, Development and Therapy·Martin SchiestlFritz Sörgel
Sep 8, 2017·British Journal of Nursing : BJN·Caroline Moore
Sep 21, 2017·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Eline van OverbeekeIsabelle Huys

❮ Previous
Next ❯

Citations

Jan 12, 2021·Saudi Pharmaceutical Journal : SPJ : the Official Publication of the Saudi Pharmaceutical Society·Mohammed A OmairAbdulrazaq Al Jazaeri

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Diabetes, Obesity & Metabolism
J H DeVriesLutz Heinemann
Current Pharmaceutical Design
Sizheng ZhaoRobert J Moots
© 2022 Meta ULC. All rights reserved